William Hyun

William (Bill) Hyun is a seasoned scientific advisor and investor with extensive experience in biotechnology and life sciences. Hyun served as a scientific advisor for multiple companies, including Zephyrus Biosciences, CellFE, Immusoft Corporation, Fibralign Corporation, and Accuri Cytometers, contributing to the development of innovative research tools and technologies. As a director at the University of California, San Francisco (UCSF), Hyun has led significant advancements in laboratory medicine and cell analysis for over twenty-five years. In addition, Hyun holds positions as a venture partner and board member at several startups and venture capital firms, fostering early-stage acquisitions and technology commercialization. Key contributions include involvement with Cytobank, which was acquired by Beckman/Danaher, and other successful ventures such as Intabio and Charisela Technologies.